CHANGES IN THE COAGULATION CASCADE IN PATIENTS WITH PROGRESSIVE (METABOLIC) LIVERDISEASE
- Conditions
- liver cirrhosisliver scarring1006447710019654
- Registration Number
- NL-OMON36796
- Lead Sponsor
- Medisch Universitair Ziekenhuis Maastricht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 140
Healthy controls (population A):
- minimum age of 18-years old
- decision making capacity;Patients (group B) (minimum of 18 years old) with cirrhosis, as diagnosed by a GE-specialist, due to one of the following chronic liver diseases: Primary Biliairy Sclerosis (PBS), Primary Sclerosis Cholangitis (PSC), Hepatitis B, Hepatitis C, Non-Alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liverdisease, Non-Alcoholic Steatosis Hepatitis (NASH), Haemochromatosis, Cryptogenic levercirrhosis.
For both healthy controls (population A) as patients (population B):
- proven congenital diseases concerning primary hemostasis (e.g. M. von Willebrand), defects in fibrinolysis, coagulation factor deficiencies (e.g. hemophilia A and B), vasculair defects which leed to higher bleeding risk (e.g. M. Rendu-Osler-Weber).
Patients using medication interfering with primary hemostasis or coagulation. Coagulation factor deficiencies due to malignancies, sepsis or trauma.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Thrombin Generation Curve in PPP (platelet poor plasma) and PRP (platelet rich<br /><br>plasma) using CAT<br /><br>Thrombocyte function test using the Multiplate (aggregometer)<br /><br>Measurement of the fibronolysis pathway by use of the Fibrinolysis ROTEM<br /><br>Measurement of microparticles with influence on the haemostasis.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Coagulatie parameters<br /><br>o Factor II<br /><br>o Factor VIII<br /><br>o Antitrombin</p><br>